MS drug sidelined

A MULTIPLE sclerosis drug has been taken off the market in Australia after patients in Europe developed serious inflammatory brain disorders.

The Therapeutic Goods Administration announced the recall of Zinbryta (daclizumab), which is used to delay disability and reduce the frequency of flare-ups in people with relapsing forms of MS.

While there have been no reports of adverse reactions in Australian patients, people on the medication should contact a health professional to discuss alternative treatments.